Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine kinase
with a plethora of substrates. As a modulator of several cellular processes, GSK-3 has a …

Abstract Glycogen synthase kinase-3 (GSK3) may be the busiest kinase in most cells, with
over 100 known substrates to deal with. How does GSK3 maintain control to selectively …

Glycogen synthase kinase-3 (GSK-3) is a widely expressed and highly conserved
serine/threonine protein kinase encoded in mammals by two genes that generate two …

The mood stabilizers lithium and valproic acid (VPA) are traditionally used to treat bipolar
disorder (BD), a severe mental illness arising from complex interactions between genes and …

Depression is associated with structural alterations in limbic brain regions that control
emotion and mood. Studies of chronic stress in animal models and postmortem tissue from …

Lithium has been used clinically to treat bipolar disorder for over half a century, and remains
a fundamental pharmacological therapy for patients with this illness. Although lithium's …

The mood stabilizer lithium inhibits glycogen synthase kinase-3 (GSK-3) directly or indirectly
by enhancing serine phosphorylation of both α and β isoforms. Lithium robustly protected …

The mood disorders major depressive disorder and bipolar disorder are prevalent, are
inadequately treated, and little is known about their etiologies. A better understanding of the …

Glycogen synthase kinase 3β (GSK3β), originally described as a negative regulator of
glycogen synthesis, is a molecular hub linking numerous signaling pathways in a cell …

Although traumatic brain injury (TBI) is recognized as one of the leading causes of death
from trauma to the central nervous system (CNS), no known treatment effectively mitigates its …